Somatic mutations in early onset luminal breast cancer.
- Author(s): Encinas, Giselly
- Sabelnykova, Veronica Y
- de Lyra, Eduardo Carneiro
- Hirata Katayama, Maria Lucia
- Maistro, Simone
- de Vasconcellos Valle, Pedro Wilson Mompean
- de Lima Pereira, Gláucia Fernanda
- Rodrigues, Lívia Munhoz
- de Menezes Pacheco Serio, Pedro Adolpho
- de Gouvêa, Ana Carolina Ribeiro Chaves
- Geyer, Felipe Correa
- Basso, Ricardo Alves
- Pasini, Fátima Solange
- Del Pilar Esteves Diz, Maria
- Brentani, Maria Mitzi
- Guedes Sampaio Góes, João Carlos
- Chammas, Roger
- Boutros, Paul C
- Koike Folgueira, Maria Aparecida Azevedo
- et al.
Published Web Locationhttps://doi.org/10.18632/oncotarget.25123
Breast cancer arising in very young patients may be biologically distinct; however, these tumors have been less well studied. We characterized a group of very young patients (≤ 35 years) for BRCA germline mutation and for somatic mutations in luminal (HER2 negative) breast cancer. Thirteen of 79 unselected very young patients were BRCA1/2 germline mutation carriers. Of the non-BRCA tumors, eight with luminal subtype (HER2 negative) were submitted for whole exome sequencing and integrated with 29 luminal samples from the COSMIC database or previous literature for analysis. We identified C to T single nucleotide variants (SNVs) as the most common base-change. A median of six candidate driver genes was mutated by SNVs in each sample and the most frequently mutated genes were PIK3CA, GATA3, TP53 and MAP2K4. Potential cancer drivers affected in the present non-BRCA tumors include GRHL2, PIK3AP1, CACNA1E, SEMA6D, SMURF2, RSBN1 and MTHFD2. Sixteen out of 37 luminal tumors (43%) harbored SNVs in DNA repair genes, such as ATR, BAP1, ERCC6, FANCD2, FANCL, MLH1, MUTYH, PALB2, POLD1, POLE, RAD9A, RAD51 and TP53, and 54% presented pathogenic mutations (frameshift or nonsense) in at least one gene involved in gene transcription. The differential biology of luminal early-age onset breast cancer needs a deeper genomic investigation.